Clinical Trials Browser

Completed × Ovarian Neoplasms × Topotecan × Clear all

NCT04908787 2025-09-11

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Phase 1/2 Completed

62 enrolled 29 charts

EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00170625 2024-11-12

Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer

Phase 1/2 Completed

28 enrolled 9 charts

Ovarian Neoplasms

NCT01696032 2024-08-27

SGI-110

Phase 2 Completed

120 enrolled 22 charts

Ovarian Neoplasms

NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Completed

19 enrolled 12 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02903004 2021-08-25

MITO23

Phase 3 Completed

Ovarian Neoplasms

NCT02631876 2020-10-14

FORWARD I

Phase 3 Completed

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02421588 2020-04-03

CORAIL

Phase 3 Completed

442 enrolled 33 charts

Ovarian Neoplasms

NCT00028743 2020-04-02

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00477282 2020-03-12

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

Phase 3 Completed

Neoplasms, Ovarian Neoplasms

NCT00011986 2019-04-16

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 3 Completed

4,312 enrolled 14 charts

Ovarian Neoplasms

NCT00652691 2019-04-08

Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03367182 2019-01-11

REBECA

Ovarian Neoplasms

NCT00114166 2018-07-24

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

81 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00061308 2017-06-09

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Phase 2 Completed

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT01684878 2017-05-23

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Phase 3 Completed

208 enrolled 19 charts

Ovarian Neoplasms

NCT00179712 2016-12-01

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Phase 1/2 Completed

Ovarian Neoplasms

NCT00437307 2016-09-22

HECTOR

Phase 3 Completed

Ovarian Neoplasms

NCT00045175 2016-06-23

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00006454 2015-12-23

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Phase 3 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Phase 1 Completed

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT00072267 2015-07-23

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01690598 2015-06-10

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Phase 1/2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00343044 2015-05-15

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Phase 2 Completed

40 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00550784 2014-10-07

Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00170677 2014-05-14

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT00436644 2014-04-16

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Phase 2 Completed

18 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00523432 2013-09-05

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

Phase 1 Completed

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT00003732 2013-08-12

Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00014690 2013-08-02

ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00055614 2013-06-26

Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003967 2013-05-27

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00005026 2013-05-27

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Brenner Tumor, Ovarian Neoplasms

NCT00842452 2013-04-05

Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT00316173 2012-11-27

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Phase 2 Completed

77 enrolled 14 charts

Ovarian Neoplasms, Recurrence

NCT00005051 2012-11-09

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00231855 2012-04-24

Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence, Uterine Neoplasms

NCT00250094 2011-09-07

Clinical Benefit of Topoisomerase Downregulation

Phase 1 Completed

Neoplasms, Ovarian Neoplasms

NCT00057720 2011-07-25

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT00429559 2011-07-22

Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

Phase 1/2 Completed

Neoplasms, Ovarian Neoplasms

NCT00193297 2011-05-03

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Phase 2 Completed

Ovarian Neoplasms

NCT00006391 2011-04-05

Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003297 2011-03-24

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer

Phase 1/2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00189566 2011-02-25

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00217555 2010-09-21

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00315861 2009-01-23

Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Phase 1 Completed

GynecologicThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00102375 2006-08-04

Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT00312988 2006-04-11

Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy

Phase 3 Completed

Ovarian Neoplasms